Promega adding molecular-biology capacity with new plant

Promega is building a new cGMP facility that will turn out FDA-regulated molecular biology products. The 260,000 square-foot plant will bring 100 people onto the company's payroll, Contract Pharma reports.

Based in Madison, WI, the company plans to use most of the new space for manufacturing, including fixed production lines and flexible manufacturing areas. The plant will help Promega grow, particularly in products for diagnostics makers, such as sample prep systems and reagents used in medical tests, the company said.

"Molecular biology opens doors not only to new understanding of life, but to practical applications that enhance the health of our citizens," CEO Bill Linton said in a statement. "This building is our next step in expanding our product supply capabilities worldwide."

Promega is using environmentally friendly construction practices in building the new facility. Geothermal heating and cooling, bio-retention stormwater ponds, and dark-sky compliant lighting are among them.

- read the release from Promega
- get more from Contract Pharma

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

AstraZeneca has signed a $750 million deal to produce up to 300 million doses of Oxford University's COVID-19 vaccine by year's end.

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot.